Skip to main content

Advertisement

SpringerLink
Log in

Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma

  • Original Article
  • Published:
Annals of Nuclear Medicine Aims and scope Submit manuscript

Abstract

Objective

The potential of positron emission tomography/computed tomography using 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) (62Cu-ATSM PET/CT), which was originally developed as a hypoxic tracer, to predict therapeutic resistance and prognosis has been reported in various cancers. Our purpose was to investigate prognostic value of 62Cu-ATSM PET/CT in patients with glioma, compared to PET/CT using 2-deoxy-2-[18F]fluoro-d-glucose (18F-FDG).

Method

56 patients with glioma of World Health Organization grade 2–4 were enrolled. All participants had undergone both 62Cu-ATSM PET/CT and 18F-FDG PET/CT within mean 33.5 days prior to treatment. Maximum standardized uptake value and tumor/background ratio were calculated within areas of increased radiotracer uptake. The prognostic significance for progression-free survival and overall survival were assessed by log-rank test and Cox’s proportional hazards model.

Results

Disease progression and death were confirmed in 37 and 27 patients in follow-up periods, respectively. In univariate analysis, there was significant difference of both progression-free survival and overall survival in age, tumor grade, history of chemoradiotherapy, maximum standardized uptake value and tumor/background ratio calculated using 62Cu-ATSM PET/CT. Multivariate analysis revealed that maximum standardized uptake value calculated using 62Cu-ATSM PET/CT was an independent predictor of both progression-free survival and overall survival (p < 0.05). In a subgroup analysis including patients of grade 4 glioma, only the maximum standardized uptake values calculated using 62Cu-ATSM PET/CT showed significant difference of progression-free survival (p < 0.05).

Conclusions

62Cu-ATSM PET/CT is a more promising imaging method to predict prognosis of patients with glioma compared to 18F-FDG PET/CT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Lopci E, Grassi I, Chiti A, Nanni C, Cicoria G, Toschi L, et al. PET radiopharmaceuticals for imaging of tumor hypoxia: a review of the evidence. Am J Nucl Med Mol Imaging. 2014;4:365–384.

    PubMed  PubMed Central  Google Scholar 

  2. Fujibayashi Y, Taniuchi H, Yonekura Y, Ohtani H, Konishi J, Yokoyama A. Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential. J Nucl Med. 1997;38:1155–60.

    CAS  PubMed  Google Scholar 

  3. Obata A, Yoshimi E, Waki A, Lewis JS, Oyama N, Welch MJ, et al. Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent cu-diacetyl-bis (N 4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells. Ann Nucl Med. 2001;15:499–504.

    Article  CAS  PubMed  Google Scholar 

  4. Tateishi K, Tateishi U, Sato M, Yamanaka S, Kanno H, Murata H, et al. Application of 62Cu-diacetyl-bis (N 4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma. AJNR Am J Neuroradiol. 2013;34:92 – 9.

    Article  CAS  PubMed  Google Scholar 

  5. Dehdashti F, Grigsby PW, Mintun MA, Lewis JS, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report. Int J Radiat Oncol Biol Phys. 2003;55:1233–8.

    Article  PubMed  Google Scholar 

  6. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med. 2008;49:201–5.

    Article  CAS  PubMed  Google Scholar 

  7. Dehdashti F, Mintun MA, Lewis JS, Bradley J, Govindan R, Laforest R, et al. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM. Eur J Nucl Med Mol Imaging 2003;30:844–50.

    Article  CAS  PubMed  Google Scholar 

  8. Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer. Lung Cancer. 2016;91:56–66.

    Article  PubMed  Google Scholar 

  9. Dietz DW, Dehdashti F, Grigsby PW, Malyapa RS, Myerson RJ, Picus J, et al. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study. Dis Colon Rectum. 2008;51:1641–8.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Sato Y, Tsujikawa T, Oh M, Mori T, Kiyono Y, Fujieda S, et al. Assessing tumor hypoxia in head and neck cancer by PET with 62Cu-diacetyl-bis(N 4-methylthiosemicarbazone). Clin Nucl Med. 2014;39:1027–32.

    Article  PubMed  Google Scholar 

  11. Tateishi K, Tateishi U, Nakanowatari S, Ohtake M, Minamimoto R, Suenaga J, et al. 62Cu-diacetyl-bis (N 4-methylthiosemicarbazone) PET in human gliomas: comparative study with [18F]fluorodeoxyglucose and l-methyl-[11C]methionine PET. AJNR Am J Neuroradiol. 2014;35:278 – 84.

    Article  CAS  PubMed  Google Scholar 

  12. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–8.

    Article  CAS  PubMed  Google Scholar 

  13. Chiang GC, Galla N, Ferraro R, Kovanlikaya I. The added prognostic value of metabolic tumor size on FDG-PET at first suspected recurrence of glioblastoma multiforme. J Neuroimaging. 2017;27:243–7.

    Article  PubMed  Google Scholar 

  14. Leiva-Salinas C, Schiff D, Flors L, Patrie JT, Rehm PK. FDG PET/MR imaging coregistration helps predict survival in patients with glioblastoma and radiologic progression after standard of care treatment. Radiology. 2017;283:508 – 14.

    Article  PubMed  Google Scholar 

  15. Colavolpe C, Metellus P, Mancini J, Barrie M, Bequet-Boucard C, Figarella-Branger D, et al. Independent prognostic value of pre-treatment 18-FDG-PET in high-grade gliomas. J Neurooncol. 2012;107:527 – 35.

    Article  PubMed  Google Scholar 

  16. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomilly R, et al. Volumetric analysis of 18F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;42:1667–73.

    Google Scholar 

  17. Toyonaga T, Yamaguchi S, Hirata K, Kobayashi K, Manabe O, Watanabe S, et al. Hypoxic glucose metabolism in glioblastoma as a potential prognostic factor. Eur J Nucl Med Mol Imaging. 2017;44:611–9.

    Article  CAS  PubMed  Google Scholar 

  18. Kawai N, Lin W, Cao WD, Ogawa D, Miyake K, Haba R, et al. Correlation between 18F-fluoromisonidazole PET and expression of HIF-1α and VEGF in newly diagnosed and recurrent malignant gliomas. Eur J Nucl Med Mol Imaging. 2014;41:1870–8.

    Article  CAS  PubMed  Google Scholar 

  19. Swanson KR, Chakraborty G, Wang CH, Rockne R, Harpold HLP, Muzi M, et al. Complementary but distinct roles for MRI and 18F-fluoromisonidazole PET in the assessment of human glioblastomas. J Nucl Med. 2009;50:36–44.

    Article  PubMed  Google Scholar 

  20. Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, et al. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Carlin S, Zhang H, Reese M, Ramos NN, Chen Q, Ricketts SA. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers. J Nucl Med. 2014;55:515 – 21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. O’Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N 4-methylthiosemicarbazone) positron emission tomography: comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys. 2005;61:1493–502.

    Article  PubMed  Google Scholar 

  23. Furukawa T, Yuan Q, Jin ZH, Aung W, Yoshii Y, Hasegawa S, et al. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-d-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone]. Oncol Rep. 2015;34:1379–87.

    Article  CAS  PubMed  Google Scholar 

  24. Troost EG, Laverman P, Kaanders JH, Philippens M, Lok J, Oyen WJ, et al. Imaging hypoxia after oxygenation-modification: comparing [18F]FMISO autoradiography with pimonidazole immunohistochemistry in human xenograft tumors. Radiother Oncol. 2006;80:157 – 64.

    Article  CAS  PubMed  Google Scholar 

  25. Busk M, Mortensen LS, Nordsmark M, Overgaard J, Jakobsen S, Hansen KV, et al. PET hypoxia imaging with FAZA: reproducibility at baseline and during fractionated radiotherapy in tumour-bearing mice. Eur J Nucl Med Mol Imaging. 2013;40:186 – 97.

    Article  CAS  PubMed  Google Scholar 

  26. Li F, Jorgensen JT, Forman J, Hansen AE, Kjaer A. 64Cu-ATSM reflects pO2 levels in human head and neck cancer xenografts but not in colorectal cancer xenografts: comparison with 64CuCl2. J Nucl Med. 2016;57:437 – 43.

    Article  CAS  PubMed  Google Scholar 

  27. Colombie M, Gouard S, Frindel M, Vidal A, Cherel M, Kraeber-Bodere F, et al. Focus on the controversial aspects of 64Cu-ATSM in tumoral hypoxia mapping by PET imaging. Front Med (Lausanne). 2015;2:58. https://doi.org/10.3389/fmed.2015.00058.

    Google Scholar 

  28. Bonekamp D, Deike K, Wiestler B, Wick W, Bendszus M, Radbruch A, et al. Association of overall survival in patients with newly diagnosed glioblastoma with contrast-enhanced perfusion MRI: comparison of intraindividually matched T1- and T2 *-based bolus techniques. J Magn Reson Imaging. 2015;42:87–96.

    Article  PubMed  Google Scholar 

  29. Coban G, Mohan S, Kural F, Wang S, O’Rourke DM, Poptani H. Prognostic value of dynamic susceptibility contrast-enhanced and diffusion-weighted MR imaging in patients with glioblastomas. AJNR Am J Neuroradiol. 2015;36:1247–52.

    Article  CAS  PubMed  Google Scholar 

  30. Jordan CT, Guzman ML, Noble M. Cancer stem cells. N Engl J Med. 2006;355:1253–61.

    Article  CAS  PubMed  Google Scholar 

  31. Yoshii Y, Furukawa T, Kiyono Y, Watanabe R, Waki A, Mori T, et al. Copper-64-diacetyl-bis (N 4-methylthiosemicarbazone) accumulates in rich regions of CD133+ highly tumorigenic cells in mouse colon carcinoma. Nucl Med Biol. 2010;37:395–404.

    Article  CAS  PubMed  Google Scholar 

  32. Ikawa M, Okazawa H, Tsujikawa T, Matsunaga A, Yamamura O, Mori T, et al. Increased oxidative stress is related to disease severity in the ALS motor cortex: A PET study. Neurology. 2015;84:2033–9.

    Article  CAS  PubMed  Google Scholar 

  33. Indo HP, Davidson M, Yen HC, Suenaga S, Tomita K, Nishii T, et al. Evidence of ROS generation by mitochondria in cells with impaired electron transport chain and mitochondrial DNA damage. Mitochondrion. 2007;7:106 – 18.

    Article  CAS  PubMed  Google Scholar 

  34. Okon IS, Zou MH. Mitochondrial ROS and cancer drug resistance: implications for therapy. Phamacol Res. 2015;100:170–4.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by a Grant-in-Aid for Cancer Research (21-5-2) from the Ministry of Health, Labor and Welfare and was also supported in part by the Ministry of Education, Culture, Sports, Science and Technology, KAKENHI Grant (15K19977 to Makoto Ohtake). In addition, this work was supported in part by grants from Scientific Research Expenses for Health and Welfare Programs, the Grant-in-Aid for Cancer Research from the Ministry of Health, Labor and Welfare, No. 15K09885, the Scientific Research Expenses for Health and Welfare Programs, No. 29-A-3 (Takashi Terauchi and Ukihide Tateishi: squad leaders), Practical Research for Innovative Cancer Control and Project Promoting Clinical Trials for Development of New Drugs by Japan Agency for Medical Research and Development (AMED).

Author information

Authors and Affiliations

  1. Department of Diagnostic Radiology and Nuclear Medicine, Tokyo Medical and Dental University, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan

    Akira Toriihara, Tomohiro Yoneyama, Yoshio Kitazume & Ukihide Tateishi

  2. Departments of Neurosurgery, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Makoto Ohtake, Kensuke Tateishi & Nobutaka Kawahara

  3. Departments of Radiology, Graduate School of Medicine, Yokohama City University, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan

    Ayako Hino-Shishikura & Tomio Inoue

Authors
  1. Akira Toriihara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Makoto Ohtake
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kensuke Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ayako Hino-Shishikura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomohiro Yoneyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Kitazume
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomio Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Nobutaka Kawahara
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ukihide Tateishi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ukihide Tateishi.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary material 1 (DOCX 17 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Toriihara, A., Ohtake, M., Tateishi, K. et al. Prognostic implications of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/CT in patients with glioma. Ann Nucl Med 32, 264–271 (2018). https://doi.org/10.1007/s12149-018-1241-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12149-018-1241-4

Keywords

Search

Navigation